Daito Pharmaceutical Co., Ltd. Logo

Daito Pharmaceutical Co., Ltd.

Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.

4577 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
富山市八日町326番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daito Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company operates an integrated business model that covers the entire production process, from active pharmaceutical ingredients (APIs) to finished formulation products, including powders, granules, and tablets. Its portfolio consists of generic drugs (both prescription and over-the-counter), health foods, and quasi-drugs. In addition to its own products, Daito serves other pharmaceutical firms by supplying APIs for generic products and offering contract manufacturing (CMO) services. The company emphasizes a stable supply of high-quality products managed by a strict quality assurance system.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Daito Pharmaceutical Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-27 08:15
Regulatory News Service
確認書
Japanese 8.3 KB
2025-08-27 08:13
Annual Report
有価証券報告書-第83期(2024/06/01-2025/05/31)
Japanese 1.4 MB
2025-06-12 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.3 KB
2025-05-13 09:22
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.0 KB
2025-04-11 08:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-03-12 08:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.7 KB
2025-02-13 08:56
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-01-17 09:04
Regulatory News Service
臨時報告書
Japanese 34.3 KB
2025-01-10 08:56
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-01-10 08:54
Interim Report
半期報告書-第83期(2024/06/01-2025/05/31)
Japanese 194.9 KB
2024-09-02 08:00
Regulatory News Service
臨時報告書
Japanese 21.8 KB
2024-08-30 07:43
Registration Form
確認書
Japanese 8.2 KB
2024-08-30 07:41
Governance Information
内部統制報告書-第82期(2023/06/01-2024/05/31)
Japanese 22.1 KB
2024-08-30 07:38
Annual Report
有価証券報告書-第82期(2023/06/01-2024/05/31)
Japanese 1.3 MB
2024-08-28 09:43
Regulatory News Service
臨時報告書
Japanese 20.4 KB

Automate Your Workflow. Get a real-time feed of all Daito Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Daito Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway ULTI
Zentiva 2 Logo
European provider of high-quality, affordable generic and over-the-counter medicines.
Slovakia SKF
Zentiva S.A. Logo
Develops and distributes affordable generic, OTC, and specialty medicines across Europe.
Romania SCD
ZERIA PHARMCEUTICAL CO., LTD. Logo
Develops and distributes prescription & consumer healthcare products in Europe and Asia.
Japan 4559
株式会社PRISM BioLab Logo
A biotech creating novel drugs by targeting previously "undruggable" protein interactions.
Japan 206A

Talk to a Data Expert

Have a question? We'll get back to you promptly.